A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients

NCT02204722 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

55

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision to halt the study.

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG: 600mg/day of Imatinib
DRUG: 400mg/day of Imatinib

Sponsor

Dong-A ST Co., Ltd.

Collaborators

[object Object]